CDSCO Panel nod to AstraZeneca Olaparib for BRCA Mutated HER2 Negative Breast Cancer
Based on the scientific data provided by the drug maker AstraZeneca, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has given its nod for the additional indication of the anticancer Drug Olaparib film coated tablet 100/150 mg for breast cancer with adult patients with BRCA-mutated HaeR2- negative.This came after the firm-presented...
Based on the scientific data provided by the drug maker AstraZeneca, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has given its nod for the additional indication of the anticancer Drug Olaparib film coated tablet 100/150 mg for breast cancer with adult patients with BRCA-mutated HaeR2- negative.
This came after the firm-presented interim report of the ongoing Phase IV clinical trial of Olaparib Film Coated Tablet 100/150 mg as per the condition of the permission (IMP-ND-189/2018) granted to the firm.
For more details, check out the fulls story on the link below:
AstraZeneca Olaparib Gets CDSCO Panel Okay For BRCA Mutated HER2 Negative Breast Cancer
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd